Synlogic Presents Data on Hyperoxaluria Program at American Society of Nephrology Kidney Week 2021
- Additional clinical data presented on SYNB8802 in a healthy volunteer model of diet-induced hyperoxaluria -
- Phase 1b study of SYNB8802 in enteric hyperoxaluria patients is ongoing with results expected in 2022 -
The two posters will be available throughout the duration of the conference:
- Poster #3605649: Relationship Between 24-hr Urinary Oxalate and Incident Chronic Kidney Disease Among Patients with and without Underlying Gastrointestinal Disease
- In one of the largest longitudinal retrospective observational cohort studies of urinary oxalate to date, >750,000 individuals with at least one 24-hr urine collection were identified. The risk of incident chronic kidney disease increased with increasing 24-hour urine oxalate (UOx) excretion, with an odds ratio of 1.67 (95% CI: 1.51, 1.86) for the highest UOx group compared with the lowest UOx group.
- Poster #3605510: Proof-of-Concept Study of Oxalate-Consuming Synthetic Biotic Medicine SYNB8802 in Enteric Hyperoxaluria after Roux-en-Y Surgery
- As previously disclosed, the dose of 3e11 live cells was identified in healthy volunteers and demonstrated to be well-tolerated. At this dose, the percent reduction from baseline UOx levels was -28.6% (90% CI: -42.4 to -11.6) compared to placebo in diet-induced hyperoxaluria.
- Part B of the study is a double-blind, placebo-controlled crossover study of SYNB8802 in subjects with enteric hyperoxaluria and a history of Roux-en-Y gastric bypass surgery. Part B remains ongoing and results are expected in 2022.
Posters will be made available on the
About Enteric Hyperoxaluria
Enteric Hyperoxaluria is an acquired metabolic disorder caused by increased absorption of dietary oxalate, which is present in many healthy foods, making it almost impossible to control with diet alone. Enteric Hyperoxaluria often occurs as a result of a primary insult to the bowel, such as inflammatory bowel disease, short bowel syndrome, or as a result of surgical procedures such as Roux-en-Y bariatric weight-loss surgery. Enteric Hyperoxaluria results in dangerously high levels of urinary oxalate, which causes progressive kidney damage, kidney stone formation, and nephrocalcinosis. There are no approved treatment options.
Synlogic™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering,
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to
INVESTOR & MEDIA CONTACT: Daniel Rosan, Synlogic, Inc., Phone: 617-401-9152, Email: email@example.com